ArticleMetabolism: clinical and experimental2023
Loss of CEACAM1 in endothelial cells causes hepatic fibrosis.
Article in Metabolism: clinical and experimental, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 14 citations in OpenAlex.
- Deletion of CEACAM1 does not affect retinal and choroidal morphology or transcriptome.Cell and tissue research · 2026Article
- 3D-printed PRP-infused double-network hydrogels orchestrate inflammation resolution and vascular regeneration in infected wounds.Materials today. Bio · 2026Article
- Diminished CEACAM1 level plays a critical role in age-related hepatic fibrosis.Mechanisms of ageing and development · 2025Article
- Cell-specific regulation of insulin action and hepatic fibrosis by CEACAM1.Metabolism and target organ damage · 2024Article
- Current investigation of carcinoembryonic antigen cell adhesion molecule (CEACAM) biology summary of the 32nd CEA symposium: 20-23 September 2024. Würzburg, Germany.European journal of clinical investigation · 2024Article
- Conditional deletion of CEACAM1 in hepatic stellate cells causes their activation.Molecular metabolism · 2024Article
- CEACAM1: Shielding the liver against fibrosis.European journal of clinical investigation · 2024Article
- Loss of CEACAM1 in hepatocytes causes hepatic fibrosis.European journal of clinical investigation · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 6 institutions in 4 countries.
Funding
Abstract
objectivesHepatocytic CEACAM1 plays a critical role in NASH pathogenesis, as bolstered by the development of insulin resistance, visceral obesity, steatohepatitis and fibrosis in mice with global Ceacam1 (Cc1) deletion. In contrast, VECadCre+Cc1
methodsVECadCre+Et1.Cc1
resultsHepatic fibrosis and inflammatory infiltration developed in VECadCre+Cc1
conclusionsThe data demonstrated that endothelial CEACAM1 plays a key role in preventing hepatic fibrogenesis by reducing autocrine endothelin1 production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.